FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 30, 1996
WARNER-LAMBERT COMPANY
(Exact name of registrant as specified in its charter)
Delaware 1-3608 22-1598912
(State or other (Commission (IRS Employer
Jurisdiction of File Number) Identification
incorporation) No.)
201 Tabor Road, Morris Plains, New Jersey 07950
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (201) 540-2000
Item 5. Other Events.
On July 1, 1996, the Registrant issued a press release
announcing that the Company had purchased Glaxo Wellcome plc's U.S.
and European interests in the Warner Wellcome over-the-counter joint
ventures (formed in 1994 with Wellcome plc). Purchase agreements for
Glaxo Wellcome's interest in Canada, Mexico, Australia and New Zealand
are expected to be signed in the third quarter, 1996. The purchase
price for the entire transaction is $1.05 billion.
The Registrant also announced the restructuring of Warner-
Lambert's joint venture arrangements with Glaxo Wellcome to market
Glaxo Welcome's Rx to OTC switch products. The joint venture
arrangements will now include Wellcome's Rx to OTC products.
The foregoing summary is qualified in its entirety by the
complete text of the press release and the Amended and Restated Global
Principles Agreement dated as of June 30, 1996, each of which is
attached hereto.
Item 7. Financial Statements, Pro Forma Financial Information
and Exhibits.
(c) Exhibits
(10) Material contracts.
(a) Amended and Restated Global Principles Agreement, dated
as of June 30, 1996, between Warner-Lambert Company and Glaxo Wellcome
plc.
(99) Additional Exhibits.
(a) Press Release dated July 1, 1996.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
WARNER-LAMBERT COMPANY
(Registrant)
Date: July 1, 1996 By: /s/ Joseph E. Lynch
-------------------------
JOSEPH E. LYNCH
Vice President and
Controller
Exhibit Index
Exhibit No. Exhibit Page No.
- ----------- --------------------------- --------
(10) Material contracts.
(a) Amended and Restated
Global Principles Agreement,
dated as of June 30, 1996,
between Warner-Lambert
Company and Glaxo Wellcome
plc.
(99) Additional Exhibits.
(a) Press Release dated
July 1, 1996.